NL-201 + Pembrolizumab Injection [Keytruda]
Phase 1Completed 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Solid Tumor
Conditions
Solid Tumor, Advanced Solid Tumor
Trial Timeline
Apr 26, 2021 → Aug 15, 2024
NCT ID
NCT04659629About NL-201 + Pembrolizumab Injection [Keytruda]
NL-201 + Pembrolizumab Injection [Keytruda] is a phase 1 stage product being developed by Neurogene for Solid Tumor. The current trial status is completed. This product is registered under clinical trial identifier NCT04659629. Target conditions include Solid Tumor, Advanced Solid Tumor.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04659629 | Phase 1 | Completed |
Competing Products
20 competing products in Solid Tumor